Stay updated on Cabozantinib and Immunotherapy in Genitourinary Tumors Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib and Immunotherapy in Genitourinary Tumors Clinical Trial page.

Latest updates to the Cabozantinib and Immunotherapy in Genitourinary Tumors Clinical Trial page
- Check3 days agoChange DetectedUpdates the ClinicalTrials.gov page’s displayed revision identifier (e.g., version v3.5.2 to v3.5.3), reflecting a site/software release rather than a change to the trial record.SummaryDifference0.0%

- Check10 days agoChange DetectedAdded a new release entry on 2026-04-13 with Revision: v3.5.2, replacing the previous Revision: v3.5.0 dated 2026-04-08.SummaryDifference0.1%

- Check17 days agoChange DetectedStudy record dates were updated with new entries on 2026-04-08 and 2026-04-09, and older entries were removed on 2026-04-02 and 2026-04-03.SummaryDifference0.1%

- Check24 days agoChange DetectedAdded updates dated 2026-04-02 and 2026-04-03, and removed updates dated 2026-03-26 and 2026-03-27.SummaryDifference0.1%

- Check31 days agoChange DetectedAdditions on 2026-03-26 and 2026-03-27 introduce Urinary bladder small cell neuroendocrine carcinoma as a listed condition; deletions on 2026-03-19 and 2026-03-20 remove two previously listed items, updating the study's documented condition scope.SummaryDifference0.1%

- Check38 days agoChange DetectedPage revision updated to v3.5.0; prior revision v3.4.3 was removed.SummaryDifference0.1%

Stay in the know with updates to Cabozantinib and Immunotherapy in Genitourinary Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib and Immunotherapy in Genitourinary Tumors Clinical Trial page.